Vitamin D has been demonstrated to have an immunomodulatory role in
cystic fibrosis with
allergic bronchopulmonary aspergillosis (ABPA). Herein, we evaluate supplemental
vitamin D in acute-stage ABPA complicating
asthma. Thirty subjects were randomised to receive either
prednisolone (n = 15, control) or
prednisolone and oral
vitamin D (n = 15, intervention arm). Serum
vitamin D levels were significantly higher in the intervention versus the control arm, following
therapy. The mean decline in total
IgE at 2 months (primary outcome) was 10% higher in the intervention arm than the control arm; however, this was not statistically significant (48.6% vs 38.1%, P = 0.27). The percentage decline in total
IgE after 4 and 6 months of randomisation was also similar in the two arms. There was no difference in
asthma exacerbations (0 vs 2, intervention vs control; P = 0.16). No ABPA exacerbation occurred in either arm. The other outcomes including the Th2 (IL-4, IL-6 and IL-10) and Th17 (IL-17)
cytokine levels were similar in the two groups. None of the participants experienced hypervitaminosis D. There was no significant improvement in the clinical or immunological outcomes following
vitamin D supplementation. A larger trial is required to ascertain the role of
vitamin D in ABPA complicating
asthma [Clinicaltrials.gov: NCT03133299].